U.S. Interactive Media and Services Stock News

Estée Lauder Companies (NYSE:EL) is facing new UK litigation tied to its Jo Malone business. The case includes allegations of insider trading and fiduciary breaches involving senior executives. The legal action is emerging while the company is engaged in public merger negotiations with Puig. For investors watching NYSE:EL, these governance allegations arrive at a sensitive time. The stock last closed at $80.83, with shares down 24.3% year to date and 57.3% over three years, while still up...

CorMedix (CRMD) has opened 2026 with Q1 revenue of US$127.4 million and basic EPS of US$0.49, set against a very large year over year earnings expansion and a move in net profit margin from 20.8% to 45% over the past 12 months. The company has seen quarterly revenue step up from US$39.1 million in Q1 2025 to US$127.4 million in Q1 2026. Trailing twelve month EPS has moved from US$0.28 at the start of 2025 to US$2.38 by Q1 2026. This gives investors a results set where wider margins and higher...

Kenvue (KVUE) has drawn investor attention after recent share performance data showed the stock flat over 1 day, down about 3% over the past week, and weaker over the past year. See our latest analysis for Kenvue. At a share price of US$17.19, Kenvue’s recent 7 day and 90 day share price returns, which declined 2.99% and 8.07% respectively, line up with a weaker 1 year total shareholder return that fell 24.68%. This suggests fading momentum as investors reassess its risk and return...

Wondering whether Enphase Energy's share price reflects its true worth, or if the recent moves have left it mispriced. The stock closed at US$48.01 after a sharp rebound, with returns of 35.4% over the past week, 50.0% over the past month and 42.3% year to date, even though the 1 year, 3 year and 5 year returns are down 3.4%, 70.7% and 66.1% respectively. Recent coverage has focused on how Enphase Energy fits into the broader semiconductor and clean energy story, with investors reacting to...

For investors wondering whether BlackRock, at around US$1,104 per share, represents value or simply a premium price tag, this article outlines what the current data can and cannot indicate about that question. The stock has delivered returns of 3.4% over the past week, 4.7% over the past month, 1.7% year to date and 14.6% over the past year, with 3 year and 5 year returns of 77.0% and 47.3% respectively. These figures naturally raise questions about how much potential future upside or...

Wondering whether Global Net Lease at about US$9.20 is offering fair value or an opportunity? This article walks through what the current price may be implying. The stock is up 0.9% over the last week, has slipped 3.1% over the last month, yet sits 4.3% higher year to date and 26.3% higher over the past year. These moves can change how you think about both upside and risk. Recent headlines have focused on Global Net Lease as part of broader discussions around US listed real estate investment...

Fate Therapeutics (FATE) opened 2026 with Q1 results showing revenue of about US$1.3 million and a basic EPS loss of US$0.26, alongside a net loss of US$31.2 million. Over recent quarters the company has seen quarterly revenue sit in a tight band around US$1.3 million to US$1.9 million, while basic EPS losses have moved between roughly US$0.26 and US$0.44 and trailing twelve month EPS has been around a US$1.09 loss. With the stock trading near US$1.90, the key question for investors is...

Avista (AVA) is drawing fresh attention after Avista Utilities started operating a community-based microgrid at Spokane’s Dr. Martin Luther King Jr. Family Outreach Center. The project combines solar, battery storage, and natural gas to support energy resilience. See our latest analysis for Avista. At a share price of $41.16, Avista has delivered a 6.30% year to date share price return, while the 1 year total shareholder return of 11.34% suggests interest has been building around its recent...

Enovix (ENVX) opened Q1 2026 with revenue of US$7.6 million and a basic EPS loss of US$0.18, alongside a net loss of US$38.26 million. On a trailing 12 month basis, the company generated US$34.32 million of revenue and a basic EPS loss of US$0.81 tied to a US$171.49 million net loss. Over recent quarters, the company has seen revenue range from US$5.10 million to US$11.27 million with quarterly basic EPS losses between US$0.12 and US$0.26. This provides a clear view of how growth and losses...

Akamai Technologies (NasdaqGS:AKAM) has agreed to acquire LayerX, a provider of browser-based AI usage control and secure enterprise browser technology. The deal extends Akamai’s Zero Trust portfolio into browser-level protection for generative AI applications used inside enterprises. The acquisition targets growing enterprise concerns around how employees access and use AI tools through their web browsers. Akamai Technologies, trading at $155.67, has seen strong recent share price...

Bullish (BLSH) opened 2026 with Q1 revenue of US$77.5 million, a basic EPS loss of US$3.85, and a net loss of US$581.7 million, setting a tough but clear baseline for investors watching how the story develops from here. Over the past year, the company has seen quarterly revenue move from US$39.3 million in Q4 2024 to US$77.5 million in Q1 2026, while EPS has swung between a profit of US$1.39 and losses such as US$3.85, highlighting how quickly margins can shift as the business scales. With...

Black Rock Coffee Bar (BRCB) opened Q1 2026 with revenue of US$55.5 million and basic EPS of US$0.02, alongside net income of US$0.4 million. These results put fresh numbers behind a company that has recently moved into profitability on a trailing twelve month basis. The company has seen quarterly revenue move from US$42.8 million in Q4 2024 to US$51.5 million in Q3 2025 and then US$53.6 million in Q4 2025. Trailing twelve month EPS shifted from a loss of US$0.33 in Q2 2025 to a small profit...

In the first quarter of 2026, monday.com reported revenue of US$351.27 million and net income of US$28.03 million, while also lifting its full‑year revenue outlook. Ahead of this earnings release, the company unveiled its largest product overhaul yet, rebranding as an AI Work Platform with native, configurable AI agents and a new consumption-based pricing model aimed at monetizing AI usage across its customer base. We’ll now examine how monday.com’s launch of its AI Work Platform and...

REGENXBIO (RGNX) Q1 2026 earnings snapshot REGENXBIO (RGNX) has just posted Q1 2026 results with revenue of US$6.4 million and a basic EPS loss of US$1.72, against a trailing twelve month basic EPS loss of US$5.59 on revenue of US$87.8 million. Over recent quarters the company has reported revenue of US$89.0 million in Q1 2025, followed by US$21.4 million in Q4 2024. Basic EPS moved from a profit of US$0.12 in Q1 2025 to a loss of US$1.01 in Q4 2024. These figures are likely to draw investor...

Leggett & Platt, Incorporated has reported past first-quarter 2026 results showing sales of US$918.2 million, down from US$1,022.1 million a year earlier, with net income falling from US$30.6 million to US$20 million. The simultaneous decline in both revenue and profitability gives investors a fresh data point on how the company is managing current demand conditions and cost pressures. We’ll now examine how this quarter’s weaker sales and earnings reshape Leggett & Platt’s investment...

Recent share performance and business profile Novo Nordisk (NYSE:NVO) has drawn investor attention after a mixed stretch for the stock, with the share price down 12.6% year to date yet up 16.5% over the past month. The Denmark based pharmaceutical group reports US$327.8b in revenue and US$121.96b in net income, primarily from its Diabetes and Obesity Care segment, alongside a smaller Rare Disease business. See our latest analysis for Novo Nordisk. At a share price of US$45.80, Novo Nordisk...

Nebius Group (NasdaqGS:NBIS) has opened 2026 with Q1 revenue of US$399 million and Basic EPS of US$2.40, alongside net income of US$621.2 million, setting a clear marker after a volatile run of prior quarters. The company has seen revenue move from US$55.3 million in Q1 2025 and US$35.2 million in Q4 2024 to US$399 million in Q1 2026, with Basic EPS shifting from a loss of US$0.48 in Q1 2025 and a loss of US$0.58 in Q4 2024 to a profit of US$2.40. This puts the focus firmly on how sustainable...

Cooper Companies (NasdaqGS:COO) has appointed Paul Keel to its Board of Directors. Keel will also serve on the Board’s Audit Committee. The appointment brings experience from senior executive roles at major medical technology and industrial companies. For investors watching Cooper Companies at a share price of $60.38, this board change comes after a period of weak stock performance. The stock is down 15.7% over the past 30 days, 25.6% year to date, and 25.9% over the past year, with a 37.9%...

SS Innovations International (NasdaqCM:SSII) opened 2026 with Q1 revenue of about US$11.1 million and a basic EPS loss of US$0.02, while trailing 12 month figures show revenue of roughly US$48.5 million and a basic EPS loss of US$0.05. Over the past reported quarters, revenue has ranged from about US$5.1 million in Q1 2025 to US$14.5 million in Q4 2025, with basic EPS losses moving between roughly US$0.00 and US$0.03 per share. Investors are therefore likely to focus on how efficiently that...

Escalating conflict in the Middle East, including closures around the Strait of Hormuz and issues at Iran’s Kharg Island terminal, has pushed oil prices higher and put Exxon Mobil (XOM) firmly back in focus for investors. See our latest analysis for Exxon Mobil. At a share price of US$152.78, Exxon Mobil has logged a 24.57% year to date share price return. Its 1 year total shareholder return of 45.19% and 5 year total shareholder return of 212.06% point to strong longer term compounding...

Biohaven Ltd. reported first-quarter 2026 results in the past, narrowing its net loss to US$130.53 million from US$221.68 million a year earlier, while loss per share from continuing operations declined to US$0.88 from US$2.17. On the same day, Biohaven filed an omnibus shelf registration covering a wide range of securities, potentially giving the company considerable flexibility in how it may access capital in the future. With these earnings and the broad shelf registration in mind, we’ll...

In May 2026, Valpak Intelligence announced that its New Mover and New Business audience segments became directly available in LiveRamp’s Data Marketplace, giving marketers, brands, and agencies streamlined access to its postal-anchored identity data across major DSPs, SSPs, CTV platforms, and CRM destinations without separate licensing agreements. This partnership brings Valpak’s decades-built household identity spine, spanning approximately 135 million households and hundreds of millions of...

Keros Therapeutics (KROS) has just posted Q1 2026 results, with revenue of US$0.4 million, a basic EPS loss of US$1.21 and a net loss of US$23.7 million, setting the tone for the quarter at a share price of US$10.99. The company has seen quarterly revenue move from US$211.2 million in Q1 2025 to US$0.4 million in Q1 2026, while basic EPS shifted from a profit of US$3.66 to a loss of US$1.21. This puts the spotlight on how changes in revenue expectations and potential margin developments could...

In early May 2026, Vertex Pharmaceuticals filed a new US$2.87 billion shelf registration for 6,400,000 common shares tied to its employee stock ownership plan after closing several earlier ESOP-related shelf programs, alongside reporting first-quarter 2026 revenue of US$2,986.9 million and net income of US$1,031.4 million. At the same time, Vertex expanded access for its one-time CRISPR/Cas9 therapy CASGEVY through a reimbursement agreement with Germany’s GKV-Spitzenverband and reaffirmed...